Organization
Sinotau Pharmaceutical Group
6 clinical trials
Clinical trial
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With Inoperable, Progressive, , Well Differentiated， Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine TumoursStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Evaluation of XTR004 as a Novel 18F-labeled PET Myocardial Perfusion Imaging (MPI) Tracer in Diagnosis of Known or Suspected CAD Compared With Invasive Coronary Angiography, Fractional Flow Reserve, Index of Microcirculatory ResistanceStatus: Completed, Estimated PCD: 2023-05-09
Clinical trial
Exploratory Application of XTR003 as a Novel PET Myocardial Fatty Acid Metabolism Imaging Agent for the Detection of Viable MyocardiumStatus: Completed, Estimated PCD: 2023-03-04
Clinical trial
A Clinical Study to Evaluate the Safety and Efficacy of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Somatostatin Receptor Positive Neuroendocrine NeoplasmsStatus: Not yet recruiting, Estimated PCD: 2027-06-01
Clinical trial
An Open-label, Non-randomized, Single-center Study, Evaluating the Imaging Characteristics of XTR006 Injection in Non-cognitively Impaired Subjects, MCI Due to Alzheimer Disease (AD), and Mild to Moderate AD SubjectsStatus: Completed, Estimated PCD: 2023-11-28
Clinical trial
Phase I/II Study to Evaluate the Safety and Tolerability, Radiation Dosimetry and Pharmacokinetics, and Efficacy of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate CancerStatus: Recruiting, Estimated PCD: 2025-12-01